Study of feasibility of the treatment with procainamide hydrochloride and cisplatin in pregnant mice

Emanuela Ognio, Barbara Chiavarina, Miroslav Peterka, Maria A. Mariggiò, Maurizio Viale

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Cisplatin is one of the most widely utilized anticancer drugs; nevertheless its use is often hampered by the onset of serious side effects. In spite of its tight binding to DNA, great teratogenic effects do not characterize cisplatin, although its embryolethal and growth retardation activities are quite remarkable. On the basis of our previous observations, demonstrating the usefulness of procainamide hydrochloride for the protection against cisplatin toxic effects in adult mice and rats, we now analyze the feasibility of the combined treatment with cisplatin and the antiarrhythmic drug procainamide hydrochloride in pregnant mice and the possible protective action of procainamide against the embryotoxic activity of cisplatin. Our data, obtained in CD-1 dams after treatment with 8 or 12 mg/kg cisplatin ip, with or without 50 mg/kg procainamide hydrochloride iv, confirm the embryotoxic effects of cisplatin. We also demonstrate that procainamide may be administered with cisplatin without causing an increase in its embryotoxic effects, but slightly improving some embryotoxicity parameters in living embryos such as the fetal weight, the percentage of fetuses with skeletal anomalies, and the number of ossification centres. The mechanism of action of this partially protective activity seems to be linked in part to the lower cisplatin accumulation in fetal tissue, probably due to an interaction of drugs at the level of placenta, in part to the protection of procainamide against maternal toxicity of cisplatin. A relevant result of this research is the suggestion that procainamide hydrochloride might be administered in case of pregnancy to protect against the maternal toxic effects of cisplatin without an increased embryotoxic/teratogenic risk for the offspring.

Original languageEnglish
Pages (from-to)232-240
Number of pages9
JournalChemico-Biological Interactions
Volume164
Issue number3
DOIs
Publication statusPublished - Dec 15 2006

Fingerprint

Procainamide
Feasibility Studies
Cisplatin
Poisons
Fetus
Fetal Weight
Anti-Arrhythmia Agents
Drug Interactions
Osteogenesis
Pharmaceutical Preparations
Placenta
Dams
Toxicity
Rats
Embryonic Structures
Mothers

Keywords

  • Chemoprotection
  • Cisplatin
  • Embryotoxicity
  • Procainamide hydrochloride

ASJC Scopus subject areas

  • Toxicology

Cite this

Study of feasibility of the treatment with procainamide hydrochloride and cisplatin in pregnant mice. / Ognio, Emanuela; Chiavarina, Barbara; Peterka, Miroslav; Mariggiò, Maria A.; Viale, Maurizio.

In: Chemico-Biological Interactions, Vol. 164, No. 3, 15.12.2006, p. 232-240.

Research output: Contribution to journalArticle

Ognio, Emanuela ; Chiavarina, Barbara ; Peterka, Miroslav ; Mariggiò, Maria A. ; Viale, Maurizio. / Study of feasibility of the treatment with procainamide hydrochloride and cisplatin in pregnant mice. In: Chemico-Biological Interactions. 2006 ; Vol. 164, No. 3. pp. 232-240.
@article{e76bfb1fe3994e4aac912ca0dcf9f494,
title = "Study of feasibility of the treatment with procainamide hydrochloride and cisplatin in pregnant mice",
abstract = "Cisplatin is one of the most widely utilized anticancer drugs; nevertheless its use is often hampered by the onset of serious side effects. In spite of its tight binding to DNA, great teratogenic effects do not characterize cisplatin, although its embryolethal and growth retardation activities are quite remarkable. On the basis of our previous observations, demonstrating the usefulness of procainamide hydrochloride for the protection against cisplatin toxic effects in adult mice and rats, we now analyze the feasibility of the combined treatment with cisplatin and the antiarrhythmic drug procainamide hydrochloride in pregnant mice and the possible protective action of procainamide against the embryotoxic activity of cisplatin. Our data, obtained in CD-1 dams after treatment with 8 or 12 mg/kg cisplatin ip, with or without 50 mg/kg procainamide hydrochloride iv, confirm the embryotoxic effects of cisplatin. We also demonstrate that procainamide may be administered with cisplatin without causing an increase in its embryotoxic effects, but slightly improving some embryotoxicity parameters in living embryos such as the fetal weight, the percentage of fetuses with skeletal anomalies, and the number of ossification centres. The mechanism of action of this partially protective activity seems to be linked in part to the lower cisplatin accumulation in fetal tissue, probably due to an interaction of drugs at the level of placenta, in part to the protection of procainamide against maternal toxicity of cisplatin. A relevant result of this research is the suggestion that procainamide hydrochloride might be administered in case of pregnancy to protect against the maternal toxic effects of cisplatin without an increased embryotoxic/teratogenic risk for the offspring.",
keywords = "Chemoprotection, Cisplatin, Embryotoxicity, Procainamide hydrochloride",
author = "Emanuela Ognio and Barbara Chiavarina and Miroslav Peterka and Mariggi{\`o}, {Maria A.} and Maurizio Viale",
year = "2006",
month = "12",
day = "15",
doi = "10.1016/j.cbi.2006.10.001",
language = "English",
volume = "164",
pages = "232--240",
journal = "Chemico-Biological Interactions",
issn = "0009-2797",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Study of feasibility of the treatment with procainamide hydrochloride and cisplatin in pregnant mice

AU - Ognio, Emanuela

AU - Chiavarina, Barbara

AU - Peterka, Miroslav

AU - Mariggiò, Maria A.

AU - Viale, Maurizio

PY - 2006/12/15

Y1 - 2006/12/15

N2 - Cisplatin is one of the most widely utilized anticancer drugs; nevertheless its use is often hampered by the onset of serious side effects. In spite of its tight binding to DNA, great teratogenic effects do not characterize cisplatin, although its embryolethal and growth retardation activities are quite remarkable. On the basis of our previous observations, demonstrating the usefulness of procainamide hydrochloride for the protection against cisplatin toxic effects in adult mice and rats, we now analyze the feasibility of the combined treatment with cisplatin and the antiarrhythmic drug procainamide hydrochloride in pregnant mice and the possible protective action of procainamide against the embryotoxic activity of cisplatin. Our data, obtained in CD-1 dams after treatment with 8 or 12 mg/kg cisplatin ip, with or without 50 mg/kg procainamide hydrochloride iv, confirm the embryotoxic effects of cisplatin. We also demonstrate that procainamide may be administered with cisplatin without causing an increase in its embryotoxic effects, but slightly improving some embryotoxicity parameters in living embryos such as the fetal weight, the percentage of fetuses with skeletal anomalies, and the number of ossification centres. The mechanism of action of this partially protective activity seems to be linked in part to the lower cisplatin accumulation in fetal tissue, probably due to an interaction of drugs at the level of placenta, in part to the protection of procainamide against maternal toxicity of cisplatin. A relevant result of this research is the suggestion that procainamide hydrochloride might be administered in case of pregnancy to protect against the maternal toxic effects of cisplatin without an increased embryotoxic/teratogenic risk for the offspring.

AB - Cisplatin is one of the most widely utilized anticancer drugs; nevertheless its use is often hampered by the onset of serious side effects. In spite of its tight binding to DNA, great teratogenic effects do not characterize cisplatin, although its embryolethal and growth retardation activities are quite remarkable. On the basis of our previous observations, demonstrating the usefulness of procainamide hydrochloride for the protection against cisplatin toxic effects in adult mice and rats, we now analyze the feasibility of the combined treatment with cisplatin and the antiarrhythmic drug procainamide hydrochloride in pregnant mice and the possible protective action of procainamide against the embryotoxic activity of cisplatin. Our data, obtained in CD-1 dams after treatment with 8 or 12 mg/kg cisplatin ip, with or without 50 mg/kg procainamide hydrochloride iv, confirm the embryotoxic effects of cisplatin. We also demonstrate that procainamide may be administered with cisplatin without causing an increase in its embryotoxic effects, but slightly improving some embryotoxicity parameters in living embryos such as the fetal weight, the percentage of fetuses with skeletal anomalies, and the number of ossification centres. The mechanism of action of this partially protective activity seems to be linked in part to the lower cisplatin accumulation in fetal tissue, probably due to an interaction of drugs at the level of placenta, in part to the protection of procainamide against maternal toxicity of cisplatin. A relevant result of this research is the suggestion that procainamide hydrochloride might be administered in case of pregnancy to protect against the maternal toxic effects of cisplatin without an increased embryotoxic/teratogenic risk for the offspring.

KW - Chemoprotection

KW - Cisplatin

KW - Embryotoxicity

KW - Procainamide hydrochloride

UR - http://www.scopus.com/inward/record.url?scp=33751259085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751259085&partnerID=8YFLogxK

U2 - 10.1016/j.cbi.2006.10.001

DO - 10.1016/j.cbi.2006.10.001

M3 - Article

C2 - 17084828

AN - SCOPUS:33751259085

VL - 164

SP - 232

EP - 240

JO - Chemico-Biological Interactions

JF - Chemico-Biological Interactions

SN - 0009-2797

IS - 3

ER -